Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,371 | 717 | 1,284 | 1,653 | 1,318 |
| TOTAL | $1,493 | $1,007 | $1,382 | $1,762 | $1,441 |
| Non-Current Assets | |||||
| PPE Net | 13 | 48 | 103 | 168 | 227 |
| Other Non-Current Assets | 16 | 16 | 11 | 11 | 10 |
| TOTAL | $29 | $65 | $114 | $179 | $237 |
| Total Assets | $1,522 | $1,072 | $1,496 | $1,941 | $1,678 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 130 | 2,685 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 275 | 409 | 498 | 167 | 360 |
| Accrued Expenses | N/A | N/A | N/A | 142 | N/A |
| TOTAL | $502 | $3,094 | $498 | $309 | $360 |
| Non-Current Liabilities | |||||
| Long Term Debt | 170 | N/A | 2,169 | 1,731 | N/A |
| Deferred Revenues | 96 | N/A | N/A | N/A | N/A |
| TOTAL | $675 | $408 | $2,169 | $1,731 | $N/A |
| Total Liabilities | $1,177 | $3,502 | $2,667 | $2,041 | $360 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,851 | 17,775 | 13,565 | 11,627 | N/A |
| Common Shares | 38,718 | 32,858 | 32,375 | 30,602 | 28,360 |
| Retained earnings | -38,467 | -35,382 | -33,640 | -30,795 | -27,136 |
| TOTAL | $345 | $-2,431 | $-1,171 | $-99 | $1,318 |
| Total Liabilities And Equity | $1,522 | $1,072 | $1,496 | $1,941 | $1,677 |